JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.6 1.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.58

Max

4.61

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+35.28% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

12M

573M

Eelmine avamishind

3.5

Eelmine sulgemishind

4.6

Uudiste sentiment

By Acuity

50%

50%

155 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. mai 2026, 23:47 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3. mai 2026, 22:35 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3. mai 2026, 23:39 UTC

Market Talk

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3. mai 2026, 23:34 UTC

Market Talk

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3. mai 2026, 23:32 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3. mai 2026, 23:30 UTC

Market Talk

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3. mai 2026, 23:20 UTC

Market Talk

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3. mai 2026, 23:16 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3. mai 2026, 22:45 UTC

Market Talk

Global Equities Roundup: Market Talk

3. mai 2026, 22:45 UTC

Market Talk

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3. mai 2026, 22:20 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3. mai 2026, 22:08 UTC

Tulu

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3. mai 2026, 22:04 UTC

Tulu

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings A$2.64B>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3. mai 2026, 15:06 UTC

Tulu

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

35.28% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  35.28%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

155 / 347 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat